Evidence map›Paper›PMID 39222437›Full record

Trial reportRheumatology (Oxford, England)2025

Associations between 6-minute walk distance and physiologic measures and clinical outcomes in myositis-associated interstitial lung disease.

Sangmee Sharon Bae, Daniela Markovic, Didem Saygin, Daniel Sullivan, Koichi Yamaguchi, Siamak Moghadam-Kia, Chester V Oddis, Fereidoun Abtin, Grace Hyun J Kim, Galina Marder and 12 more

Registry-linked trialAbstract readMulticenter StudyRandomized Controlled Trial
PubMed Full text at PMC Publisher
In one paragraph

Trial report in Rheumatology (Oxford, England), 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT03215927 (A Randomized, Controlled Pilot Trial to Evaluate the Efficacy and Safety of Subcutaneous Abatacept in Treating Interstitial Lung Disease Associated With the Anti-synthetase Syndrome), which is not on this map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT03215927 phase2completednot on this map

A Randomized, Controlled Pilot Trial to Evaluate the Efficacy and Safety of Subcutaneous Abatacept in Treating Interstitial Lung Disease Associated With the Anti-synthetase Syndrome

TypeinterventionalSponsorRohit Aggarwal, MDRan2018 to 2023Enrolled20ConditionsMyositis, Interstitial Lung DiseaseArmsAbatacept, Placebo
3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

22 authors.

Sangmee Sharon BaeDivision of Rheumatology, Department of Medicine, David Geffen School of Medicine, University of California Los Angeles, Los Angeles, CA, USA.ORCID 0000-0002-7216-7219
Daniela MarkovicDepartment of Medicine Statistics Core, University of California Los Angeles, Los Angeles, CA, USA.ORCID 0009-0003-7128-280X
Didem SayginDivision of Rheumatology and Clinical Immunology, University of Chicago, Chicago, IL, USA.
Daniel SullivanDivision of Pulmonology and Critical Care Medicine, Department of Medicine, University of Pittsburgh School of Medicine, Pittsburgh, PA, USA.
Koichi YamaguchiDivision of Rheumatology and Clinical Immunology, Department of Medicine, University of Pittsburgh School of Medicine, Pittsburgh, PA, USA.
Siamak Moghadam-KiaDivision of Rheumatology and Clinical Immunology, Department of Medicine, University of Pittsburgh School of Medicine, Pittsburgh, PA, USA.
Chester V OddisDivision of Rheumatology and Clinical Immunology, Department of Medicine, University of Pittsburgh School of Medicine, Pittsburgh, PA, USA.
Fereidoun AbtinDepartment of Radiology, David Geffen School of Medicine, University of California Los Angeles, Los Angeles, CA, USA.
Grace Hyun J KimDepartment of Radiology, David Geffen School of Medicine, University of California Los Angeles, Los Angeles, CA, USA.ORCID 0000-0003-1225-3489
Galina MarderDepartment of Rheumatology, Northwell Health, Great Neck, NY, USA.ORCID 0000-0002-3625-1157
Swamy VenuturupalliDivision of Rheumatology, Department of Medicine, Cedars-Sinai Medical Center, Beverly Hills, CA, USA.
Paul F DellaripaDepartment of Rheumatology, Brigham and Women's Hospital BWH, Boston, MA, USA.
Sonye DanoffDivision of Pulmonary and Critical Care Medicine, Department of Medicine, John Hopkins Medicine, Baltimore, MD, USA.
Tracy DoyleDivision of Pulmonary and Critical Care Medicine BWH, Brigham and Women's Hospital BWH, Boston, MA, USA.
Gary HunninghakeDivision of Pulmonary and Critical Care Medicine BWH, Brigham and Women's Hospital BWH, Boston, MA, USA.
Joyce S LeeDepartment of Medicine, University of Colorado Denver, Aurora, CO, USA.
Jeremy FalkDivision of Pulmonary and Critical Care Medicine, Department of Medicine, Cedars-Sinai Medical Center, Beverly Hills, CA, USA.
Cheilonda JohnsonDepartment of Medicine, University of Pennsylvania, Philadelphia, PA, USA.
Jonathan GoldinDepartment of Radiology, David Geffen School of Medicine, University of California Los Angeles, Los Angeles, CA, USA.
Donald TashkinDivision of Pulmonary and Critical Care Medicine, Department of Medicine, David Geffen School of Medicine, University of California Los Angeles, Los Angeles, CA, USA.
Christina Charles-SchoemanDivision of Rheumatology, Department of Medicine, David Geffen School of Medicine, University of California Los Angeles, Los Angeles, CA, USA.
Rohit AggarwalDivision of Rheumatology and Clinical Immunology, Department of Medicine, University of Pittsburgh School of Medicine, Pittsburgh, PA, USA.ORCID 0000-0001-7531-8038

Funding

Genetic and Genomic Characterization of the Occurrence and Progression of Interstitial Lung AbnormalitiesR01HL135142 · NHLBI · BRIGHAM AND WOMEN'S HOSPITAL · PI MICHAEL H. CHO, GARY MATTHEW HUNNINGHAKE · 2017 to 2026
$7.7M
Interstitial Lung Abnormalities: Defining the Phenotype, Causes, and Consequences.R01HL111024 · NHLBI · BRIGHAM AND WOMEN'S HOSPITAL · PI HUNNINGHAKE, GARY MATTHEW · 2013 to 2022
$6.4M
Altered High-Density Lipoprotein function in Patients with Idiopathic Inflammatory MyopathiesK23AR081423 · NIAMS · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI Sangmee Bae · 2023 to 2026
$728k
AstraZenecaBristol Myers SquibbNHLBI NIH HHS R01 HL111024NHLBI NIH HHS R01 HL135142NIAMS NIH HHS K23 AR081423NIH HHS R01130974NIH HHS R01 HL111024NIH HHS R01 HL135142The Abatacept in Myositis Associated Interstitial lung disease
6 · The paper itself

Abstract

objectiveThe 6-min walk test (6MWT) is a simple test widely used to assess sub-maximal exercise capacity in chronic respiratory diseases. We explored the relationship of 6-min walk distance (6MWD) with measurements of physiological, clinical, radiographic measures in patients with myositis-associated interstitial lung disease (MA-ILD).

methodWe analysed data from the Abatacept in Myositis Associated Interstitial Lung Disease (Attack My-ILD) study, a 48-week multicentre randomized trial of patients with anti-synthetase antibodies and active MA-ILD. 6MWD, forced vital capacity (FVC), diffusing capacity (DLCO), high-resolution CT and various physician-/patient-reported outcome measures were obtained during the trial. Spearman's correlations and repeated-measures analysis with linear mixed-effects models were used to estimate the associations between 6MWD and various physiologic, clinical and radiographic parameters both cross-sectionally and longitudinally.

resultsTwenty participants with a median age of 57 years, 55% male and 85% white were analysed. Baseline 6MWD did not associate with baseline pulmonary function tests. Repeated-measures analysis showed 6MWD over time associated with FVC over time, but not with DLCO. 6MWD over time also correlated with University of California San Diego Shortness of Breath questionnaire dyspnoea score, Borg scores, as well as global disease activity and muscle strength over time. Emotional role functioning, vitality, general health and physical functioning scores by Short Form 36 also correlated with 6MWD over time.

conclusionsExploratory work in a small cohort of MA-ILD demonstrated 6MWD over time associated with parallel changes in FVC and patient-reported outcomes of dyspnoea, but not with DLCO. Larger studies are needed to validate the reliability, responsiveness and utility of the 6MWT in MA-ILD.

trial registrationClinicalTrials.gov, http://clinicaltrials.gov, NCT03215927.

Indexed as

Exercise ToleranceLung Diseases, InterstitialMyositisWalk TestAbataceptAgedCross-Sectional StudiesFemaleHumansMaleMiddle AgedPatient Reported Outcome MeasuresRespiratory Function TestsTomography, X-Ray ComputedVital CapacityAbatacept6-min walk distance6-min walk testantisynthetase syndromeinterstitial lung diseasemyositis associated interstitial lung disease

Identifiers

PMID39222437
PMCPMC12695042

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.